Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03064074
Recruitment Status : Recruiting
First Posted : February 24, 2017
Last Update Posted : January 21, 2019
Sponsor:
Collaborators:
Genzyme, a Sanofi Company
Shriners Hospitals for Children
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Hospital for Special Surgery, New York
University of California, Los Angeles
University of Nebraska
Oregon Health and Science University
University of South Florida
Information provided by (Responsible Party):
Brendan Lee, Baylor College of Medicine

Brief Summary:

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. OI can range from very severe to very mild. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems.

Transforming growth factor beta (TGF-β) is a protein important in bone formation. Fresolimumab is an antibody that can silence TGF-β . In studies with mice with OI, it has been shown that silencing TGF-β can lead to higher bone mass, quality and strength. The purpose of this study is to determine if fresolimumab is safe in the treatment of OI.


Condition or disease Intervention/treatment Phase
Osteogenesis Imperfecta Drug: Fresolimumab Phase 1

Detailed Description:

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. The current standard-of-care for severe types of OI involves the use of IV medications (bisphosphonates) and surgery to put rods in bones to strengthen them. These therapies, although often life-saving, are new and very little is known about their long-term effects on bone and other body systems.

TGF-β is a protein important in bone formation. Studies have shown that increased TGF-β activity leads to lower bone mass and strength and increased fractures. Fresolimumab is an antibody that can silence TGF-β . In studies with mice with OI, it has been shown that silencing TGF-β can lead to higher bone mass, quality and strength.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta
Actual Study Start Date : November 15, 2017
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020


Arm Intervention/treatment
Experimental: Stage 1 Low dose

There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).

At each study visit, the participant may have the following testing done:

  • Physical exam
  • Vitals
  • Blood draw for safety labs, pharmacokinetics, etc
  • If the participant is female, she will have a pregnancy test
  • EKG
  • DXA
  • Infusion of the study drug
Drug: Fresolimumab
The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Experimental: Stage 2 High dose

There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).

At each study visit, the participant may have the following testing done:

  • Physical exam
  • Vitals
  • Blood draw for safety labs, pharmacokinetics, etc
  • If the participant is female, she will have a pregnancy test
  • EKG
  • DXA
  • Infusion of the study drug
Drug: Fresolimumab
The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Experimental: Stage 2 Repeat dose every 6 months

Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.

At each study visit, participants may have the following testing done:

  • Physical exam
  • Vitals
  • Blood draw for safety labs, pharmacokinetics, etc
  • If the participant is female, she will have a pregnancy test
  • EKG
  • DXA
  • Infusion of the study drug
  • Skeletal survey
  • Peripheral quantitative CT (pQCT) of the forearm
  • Quality of Life Surveys
  • Pulmonary function test
  • Walk test
Drug: Fresolimumab
The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.

Experimental: Stage 2 Repeat doses every 3 months

Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.

At each study visit, participants may have the following testing done:

  • Physical exam
  • Vitals
  • Blood draw for safety labs, pharmacokinetics, etc
  • If the participant is female, she will have a pregnancy test
  • EKG
  • DXA
  • Infusion of the study drug
  • Skeletal survey
  • Peripheral quantitative CT (pQCT) of the forearm
  • Quality of Life Surveys
  • Pulmonary function test
  • Walk test
Drug: Fresolimumab
The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.




Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 6 months for single dose study and 12 months for repeat dose study ]
    Safety of single and repeat doses of fresolimumab will be assessed in adult patients with moderate to severe osteogenesis imperfecta


Secondary Outcome Measures :
  1. Percentage change in type 1 procollagen, N-terminal or P1NP, Osteocalcin or Ocn, and C-terminal telopeptide or CTX [ Time Frame: 6 months in single dose study and 12 months in repeat dose study ]
    Markers of bone turnover in blood will be assessed

  2. Percent change in the areal BMD at the lumbar spine and hip [ Time Frame: 6 months in single dose study and 12 months in repeat dose study ]
    Areal bone mineral density (aBMD) at the hip or the lumbar spine as measured by DXA Scan

  3. Difference in score of numeric rating scale for pain [ Time Frame: 12 months ]
    The difference between baseline values and at month 12 will be assessed in the repeat dose study only

  4. Change in ml in FEV1 [ Time Frame: 12 months ]
    The change in absolute volumes of FEV1 will be assessed between baseline and 12 months in the repeat dose study only

  5. Change in ml in FVC [ Time Frame: 12 months ]
    The change in absolute volumes of FVC will be assessed between baseline and 12 months in the repeat dose study only

  6. Percent change in volumetric bone mineral density at the radius [ Time Frame: 12 months ]
    pQCT of forearm will be performed to assess the change in volumetric bone mineral density between baseline and 12 months in the repeat dose study only.

  7. Number of meters walked in 6 minutes [ Time Frame: 12 months ]
    Standard 6 minute walk test will be performed to assess the difference between baseline and 12 months in the repeat dose study only



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Willing and able to provide signed informed consent.
  2. Are 18 years or older
  3. Have a diagnosis of moderate-to-severe OI based on various clinical features
  4. Have genetic mutations that include glycine substitution in COL1A1 or COL1A2, or pathogenic variants in CRTAP, PPIB, or LEPRE1 (if genetic information is unavailable at screening, this may be assessed at screening visit on a clinical or research basis).
  5. Females of child-bearing potential must have a negative urine pregnancy test, agree to and have the ability to use acceptable birth control method for entire duration of the study.
  6. For Males enrolled in the study, partners must agree to use an acceptable form of birth control for the entire duration of the study.

Exclusion Criteria:

  1. Fracture less than 3 months prior to the screening visit.
  2. Rodding or instruments that prevents reliable bone mineral density (BMD) assessment.
  3. Have a known unhealed fracture involving a long bone.
  4. Do not meet laboratory safety requirements such as: Vitamin D < 15 ng/dL Serum albumin-corrected calcium levels below 8 mg/dL, Hemoglobin < 10 g/dL, Platelet count < 75,000mm3;, Prothrombin time/(PT/INR) international normalized ratio > 1.5 times Upper Limit of Normal (ULN), Clinical or laboratory abnormality of Grade III or higher as assessed by CTCAE v4.0 which in the view of investigator would compromise safety.
  5. Have an EKG with QTc of > 450 ms
  6. Have a known allergy to fresolimumab.
  7. Have current clinically significant infection.
  8. Have a personal history of basal cell carcinoma, squamous cell carcinoma or keratoacanthomas, a personal history of cancer, recent or remote.
  9. Have evidence of untreated cavities or planned invasive dental work during the study period.
  10. Have had organ transplantation.
  11. Have known or suspected valvular heart disease.
  12. Plan to have skeletal surgery in the study period.
  13. Have had osteotomy 5 months prior to the screening visit.
  14. Being treated with zoledronic acid or pamidronate less than 12 months of screening OR oral bisphosphonates less than 6 months of screening OR teriparatide less than one year of screening.
  15. Being treated with systemic glucocorticoids
  16. Have autoimmune diseases being treated with glucocorticoids or other biologic agents.
  17. Enrolled in another clinical trial and receiving treatment with another investigational agent
  18. Pregnant or planning to get pregnant during the study period.
  19. Nursing mothers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03064074


Contacts
Layout table for location contacts
Contact: Dianne Dang 713-798-6694 diannen@bcm.edu

Locations
Layout table for location information
United States, Oregon
Oregon Health Science University Not yet recruiting
Portland, Oregon, United States, 97239
Contact: Melanie Abrahamson    503-494-0225    abrahamm@ohsu.edu   
Principal Investigator: Eric Orwoll, M.D.         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Dianne Dang    713-798-6694    diannen@bcm.edu   
Principal Investigator: Reid Sutton, M.D.         
Sponsors and Collaborators
Baylor College of Medicine
Genzyme, a Sanofi Company
Shriners Hospitals for Children
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Hospital for Special Surgery, New York
University of California, Los Angeles
University of Nebraska
Oregon Health and Science University
University of South Florida
Investigators
Layout table for investigator information
Study Chair: Sandesh Nagamani, M.D. Baylor College of Medicine
Study Chair: VReid Sutton, M.D. Baylor College of Medicine
Principal Investigator: Brendan Lee, M.D., Ph.D. Baylor College of Medicine

Layout table for additonal information
Responsible Party: Brendan Lee, Chairman/Professor, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT03064074     History of Changes
Other Study ID Numbers: RDCRN7706
First Posted: February 24, 2017    Key Record Dates
Last Update Posted: January 21, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteochondrodysplasias
Osteogenesis Imperfecta
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Collagen Diseases
Connective Tissue Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs